QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (82) Citing Articles via Google Scholar Google Scholar Articles by Hanisch, U. K. Articles by Quirion, R. Search for Related Content PubMed PubMed Citation Articles by Hanisch, U. K. Articles by Quirion, R.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 13, 3368-3374, Copyright © 1993 by Society for Neuroscience

ARTICLE

Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2

UK Hanisch, D Seto and R Quirion
Douglas Hospital Research Centre, Department of Psychiatry, Montreal, Quebec, Canada.

The potential of the T-cell growth factor interleukin-2 (IL-2) to modulate the release of ACh from rat hippocampus was studied in vitro, as a means to investigate the possible functional significance of this cytokine in the CNS. Hippocampal slices were superfused with Krebs' buffer medium, and endogenous ACh released into the superfusate was measured using a radioenzymatic assay. Recombinant human IL-2 present during a stimulation with 25 mM KCl altered, in a concentration- dependent manner, the evoked transmitter release. At a concentration of 15 U/ml (< or = 1 nM), IL-2 inhibited ACh release by more than 50% of the control level (evoked ACh release from the untreated contralateral hemispheres). Inhibition was observed within 20 min of tissue exposure to IL-2 and lasted for up to 1 hr. The inhibitory effect of IL-2 was reversible since transient tissue exposure to IL-2 did not affect subsequent evoked ACh release. IL-2 at this concentration also significantly decreased evoked ACh in frontal cortical slices, but was ineffective in the parietal cortex and striatum, revealing that IL-2 selectively modulates the release of ACh from certain, but not all, cholinergic nerve terminals in the CNS. At very low concentrations (1.5 mU/ml, < or = 0.1 pM), IL-2 transiently increased hippocampal evoked ACh release, resulting in a biphasic dose-response profile with no significant effect observed at 0.015 mU/ml (< or = 1 fM). Other cytokines (IL-1 alpha, IL-3, IL-5, IL-6, interferon alpha), tested in hippocampal slice incubations, failed to modulate ACh release.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. S. Auld, F. Mennicken, and R. Quirion Nerve Growth Factor Rapidly Induces Prolonged Acetylcholine Release from Cultured Basal Forebrain Neurons: Differentiation between Neuromodulatory and Neurotrophic Influences J. Neurosci., May 15, 2001; 21(10): 3375 - 3382. [Abstract] [Full Text] [PDF]

				L. Capuron, A. Ravaud, and R. Dantzer Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-{alpha} Treatments in Cancer Patients Psychosom Med, May 1, 2001; 63(3): 376 - 386. [Abstract] [Full Text] [PDF]

				L. Capuron, A. Ravaud, and R. Dantzer Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy J. Clin. Oncol., May 10, 2000; 18(10): 2143 - 2151. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help